From the Publishers of BioWorld Today
When: Monday, August 30, 2010
What Time: 2:00pm – 3:30pm ET
Where: Your office or conference room
Cost: $325 per location
Best Value!
Audio Conference PLUS Audio CD and Transcript: $479 ——
Order Now!
Speaker(s): Thomas C. Meyers
Duration: 90 Minutes
Following the Supreme Court's highly anticipated ruling in Bilski v. Kappos, many biotech companies are left wondering what Bilski means for biotechnology. Despite the narrow ruling, many questions are left unanswered as biotech companies find themselves in a state of uncertainty about the future of their patents.
- What does Bilski mean?
- What now?
- What's next for biotech patents?
In this 90-minute audio conference, Thomas C. Meyers, a Partner in Brown Rudnick's IP Group, will explain what you need to know about Bilski, from the opinions issued to the resulting implications for your biotech company. Mr. Meyers will also discuss what changes are likely in the future of biotech patents and when they may occur.
Learning Points:
- What are the key elements of the Bilski decision that could affect biotech companies?
- What does the Bilski decision mean for your existing biotech patents?
- What does Bilski mean for the "machine-or-transformation" test?
- How has the Bilski decision been received in the biotech community?
- What's next from Myriad and Prometheus?
Who Will Benefit From Attending This Audio Conference:
- ANYONE involved in biotechnology patents
- Executive management
- Strategic planning and business development professionals
- General/corporate counsel
- Regulatory/legislative affairs professionals
Level: Intermediate
Meet Your Expert!
Thomas C. Meyers has over 18 years of experience representing pharmaceutical and biotechnology companies. He advises companies and investors on creating and implementing patent strategies to promote commercial and business goals.
Mr. Meyers represents public and private companies, investors, and academic institutions in the life sciences arena. His portfolio of life science companies spans diagnostics, life science tools and technology platforms, genomics and genetics and therapeutics. He also advises companies in areas related to medical devices, organic and molecular chemistry, and optics.
Mr. Meyers speaks and writes extensively on strategic planning, partnering and patent matters, and presents frequently at major pharma and life sciences meetings. In addition, he advises pharmaceutical company analysts and serves as a resource for the press on matters relating to pharmaceutical litigation.
Registration details:
The registration fee for this audio conference is $325 per connection. You may invite as many participants from your facility as you can accommodate around your conference phone. Click here now to register. Make sure you mention code T10629 — 12054 when registering.
Can't attend the live event? A conference CD (MP3 format) is also available.
If you prefer to register, or order the CD recording (MP3 format), by phone, then call us at 1-800-688-2421 or 1-404-262-5474. And when you do, please be sure to mention your priority code: T10629 — 12054.
|
